» Articles » PMID: 27005319

Apelin-13 Administration Protects Against Ischaemia/reperfusion-mediated Apoptosis Through the FoxO1 Pathway in High-fat Diet-induced Obesity

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2016 Mar 24
PMID 27005319
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Apelin-13, an endogenous ligand for the apelin (APJ) receptor, behaves as a potent modulator of metabolic and cardiovascular disorders. Here, we examined the effects of apelin-13 on myocardial injury in a mouse model combining ischaemia/reperfusion (I/R) and obesity and explored their underlying mechanisms.

Experimental Approach: Adult male C57BL/6J mice were fed a normal diet (ND) or high-fat diet (HFD) for 6 months and then subjected to cardiac I/R. The effects of apelin-13 post-treatment on myocardial injury were evaluated in HFD-fed mice after 24 h I/R. Changes in protein abundance, phosphorylation, subcellular localization and mRNA expression were determined in cardiomyoblast cell line H9C2, primary cardiomyocytes and cardiac tissue from ND- and HFD-fed mice. Apoptosis was evaluated by TUNEL staining and caspase-3 activity. Mitochondrial ultrastructure was analysed by electron microscopy.

Key Results: In HFD-fed mice subjected to cardiac I/R, i.v. administration of apelin-13 significantly reduced infarct size, myocardial apoptosis and mitochondrial damage compared with vehicle-treated animals. In H9C2 cells and primary cardiomyocytes, apelin-13 induced FoxO1 phosphorylation and nuclear exclusion. FoxO1 silencing by siRNA abolished the protective effects of apelin-13 against hypoxia-induced apoptosis and mitochondrial ROS generation. Finally, apelin deficiency in mice fed a HFD resulted in reduced myocardial FoxO1 expression and impaired FoxO1 distribution.

Conclusions And Implications: These data reveal apelin as a novel regulator of FoxO1 in cardiac cells and provide evidence for the potential of apelin-13 in prevention of apoptosis and mitochondrial damage in conditions combining I/R injury and obesity.

Citing Articles

The Apelin/APJ System: A Potential Therapeutic Target for Sepsis.

Song Q, Wang X, Cao Z, Xin C, Zhang J, Li S J Inflamm Res. 2024; 17:313-330.

PMID: 38250143 PMC: 10800090. DOI: 10.2147/JIR.S436169.


Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson's Disease.

Silvestro S, Raffaele I, Mazzon E Int J Mol Sci. 2023; 24(22).

PMID: 38003423 PMC: 10671288. DOI: 10.3390/ijms242216233.


APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure.

Rossin D, Vanni R, Lo Iacono M, Cristallini C, Giachino C, Rastaldo R Pharmaceutics. 2023; 15(5).

PMID: 37242650 PMC: 10223849. DOI: 10.3390/pharmaceutics15051408.


The Apelinergic System: Apelin, ELABELA, and APJ Action on Cell Apoptosis: Anti-Apoptotic or Pro-Apoptotic Effect?.

Respekta N, Pich K, Dawid M, Mlyczynska E, Kurowska P, Rak A Cells. 2023; 12(1).

PMID: 36611944 PMC: 9818302. DOI: 10.3390/cells12010150.


A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients.

Winkle P, Goldsmith S, Koren M, Lepage S, Hellawell J, Trivedi A Cardiovasc Drugs Ther. 2022; 37(4):743-755.

PMID: 35460392 DOI: 10.1007/s10557-022-07328-w.


References
1.
Konstantinidis K, Whelan R, Kitsis R . Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol. 2012; 32(7):1552-62. PMC: 3835661. DOI: 10.1161/ATVBAHA.111.224915. View

2.
Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buleon M . Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008; 8(5):437-45. DOI: 10.1016/j.cmet.2008.10.003. View

3.
Zhao Y, Wang Y, Zhu W . Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol. 2011; 3(5):276-82. DOI: 10.1093/jmcb/mjr013. View

4.
Sengupta A, Molkentin J, Paik J, DePinho R, Yutzey K . FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem. 2010; 286(9):7468-78. PMC: 3045002. DOI: 10.1074/jbc.M110.179242. View

5.
Boal F, Guetzoyan L, Sessions R, Zeghouf M, Spooner R, Lord J . LG186: An inhibitor of GBF1 function that causes Golgi disassembly in human and canine cells. Traffic. 2010; 11(12):1537-51. DOI: 10.1111/j.1600-0854.2010.01122.x. View